EBS - OraSure: Well Positioned Ex-Covid Sell Side Missing The Organic Growth Drivers

• OraSure is well positioned to capture additional market share in DNA at-home testing and molecular collection device sales.
• The company offers differentiated propositions with unique exposure to the genome, microbiome and Covid-19 testing.
• Sequential growth patterns quarter/quarter serve as a good indication for the cadence of revenue volumes to be expected throughout FY2021.
• We feel shares are worth ~$23 today and the sell side and market are overlooking much of the organic growth potential Ex-Covid.
• Here we cover all of the necessary parts in the investment debate for the benefit of investors in their own reasoning.

For further details see: